Skip to main
SGHT
SGHT logo

Sight Sciences (SGHT) Stock Forecast & Price Target

Sight Sciences (SGHT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Sight Sciences Inc is positioned for positive financial growth, driven by anticipated revenue increases from its Surgical Glaucoma segment, which is expected to align with the overall market trends in minimally invasive glaucoma surgery (MIGS). The company is experiencing accelerated adoption of its TearCare System, alongside progress towards achieving profitability, which can further enhance its revenue potential. Projections for 2025 and 2026 indicate sustained revenue of $75 million and $82 million, respectively, with improvements anticipated in earnings per share (EPS), reflecting a positive trajectory for the company's financial outlook.

Bears say

Sight Sciences Inc. has reiterated its 2025 revenue guidance of $72-76 million while projecting a decline in Surgical Glaucoma revenue in the third quarter of 2025 by mid-single digits year-over-year. The company faces significant risks, including increasing competition in the minimally invasive glaucoma surgery (MIGS) market, delayed insurance coverage for its TearCare product, and ongoing cash burn without improvement. Additionally, management has decreased its adjusted operating expense guidance for 2025, which may signal challenges in maintaining operational efficiency amid these pressures.

Sight Sciences (SGHT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sight Sciences (SGHT) Forecast

Analysts have given Sight Sciences (SGHT) a Buy based on their latest research and market trends.

According to 6 analysts, Sight Sciences (SGHT) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sight Sciences (SGHT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.